Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal dose-finding of HL301 in acute bronchitis and acute exacerbations of chronic bronchitis
KCT0001239Phase 2Completed
- Sponsor
- Hanlim Pharm
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HL301 in acute bronchitis, chronic bronchitis (CB), sponsored by Hanlim Pharm. Started Feb 2014; status: completed.
02
Drugs
HL301
03
Conditions
acute bronchitischronic bronchitis (CB)
Beyond the preview
Go deeper on KCT0001239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001239.